The increase in the price target from $177 to $189 by Jefferies suggests a positive outlook on Neurocrine Biosciences' future performance. The reaffirmation of the Buy rating indicates continued confidence from the analyst, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.